Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Right. I now purchase the the vitamins individually knowing that combination works for us. I did purchase Z-Stack early on when nobody knew what to do. That combination works best as soon as you feel it coming on.
From the link you posted:
“There is no evidence that taking Z-Stack boosts immunity. Although vitamin C, one of the ingredients in Z-Stack, may help reduce the severity of colds and other respiratory infections, the dose in Z Stack is slightly lower than what has been shown to beneficial. Vitamin D and zinc in Z-Stack may be beneficial if you have low levels, but the amounts of these vitamins in Z-Stack is somewhat higher than what would be necessary to correct mild deficiency. There's no strong evidence that the quercetin in Z-Stack helps with immunity.
If you believe you need any of the ingredients in Z-Stack, it would be less expensive to purchase each individually, and you can choose a dose that is correct for your individual needs.“
You wasted your money.
Maybe you should try Balance of Nature or Prevagen.
I have purchased Z-Stack during the Covid-19 pandemic and it helped me and others in my family when exposed to covid. Not FDA approved. I always have some on hand. It is also delivered by UPS to my home. Nice👍️
All you need is Zinc, Quercetin, vitamin C & D. Same thing. It worked for us.
https://www.consumerlab.com/answers/z-stack-does-it-boost-immunity/z-stack-immunity/
Right on, georgejjl. Heck ya. Sign me up for that Amazon home delivery. People have seen enough in over 8 years of Blarcamesine drug trial results. It's proven safety record is phenomenal. We want access to Blarcamesine now. imo
No one is going to partner with this company. Pumper Mayo posted something similar with Musk empire. This buffoon can’t even deliver full data after two years of trials, and there’s still no sign of an NDA filing. Now, with a class action lawsuit looming, it’s clear the made up endpoints are a real problem. He pulls end points from his arse and thinks that he can fool the world and the FDA.
Amazon and Anavex
https://pharmacy.amazon.com
Low prices, with or without insurance
Automatic refills, delivered to your door
Pharmacists on call 24/7
See all benefits
According to Amazon's latest financial reports the company has $89.09 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
https://companiesmarketcap.com/amazon/cash-on-hand/
Good luck and GOD bless,
No one currently had the need to ship via Amazon.
Alzheimer’s therapies all seem to need infusions for some reason. So even though BP were able to ship it to your house, could the patient REALLY do it themselves?
Now, if it were pills much like those vitamins or Tylenol…….
Then again, we are getting way over our heads with even thinking of what an Amazon partnership would even do for the pps of AVXL.
Sure everyone can say that is unrealistic. Is it though? Only the two CEOs really know.
Continue on with your daily nonsense.
It's been so long it seems like that fit cut helped us out for one day but is it possible for this stuff to have a good week I mean just go up consistently 5 days in a row is that even possible?
I’ll just note that you are unable to understand the key argument in the Blum case, which is the change to AUC in AVATAR and on who’s guidance that then did not apply to the EXCELLENCE trial based on another obscure explanation by Missling. You see Missling won’t be able to explain the AUC fix and hence I would go for discovery of evidence explaining that change and it won’t be based on advice from a regulatory agency.
But ok you don’t feel mislead by Missling and don’t understand unrealised profit either from a trade that only exists in the digital realm until an action may take place that makes a realised gain or perhaps a loss. Paper admin of trades was a few years ago.
Hopefully the MAA filing and its approval chances lands in the 83% bucket, which would go a long way to fix the Missling mess and look forward.
Oh yes sad story, but do you not also see that it's not to the level of allowing a class action lawsuit to proceed and thus the case will be dismissed?
Nice chatting but I've got other stuff to do today and we're talking through each other. So I'll be on with my day.
Carry on with the negative talk on your "digital" long position.
Sounds like you rose to the lofty perch of being a docket manager. Guess that’s when the “Peter Principle” kicked in
Misleading never misses an opportunity to take his Business Development director along, but what happened to his VP, Klamer? What does he even do all day in the office?
I know! Everything Anavex and by implication their lawyers say is always right when WGT bias is applied.
Do you understand the AUC vs Baseline to EOT issues, especially when trial only had 3 sample points; baseline, a mid point and eot? Can you see its nonsense or are you able to explain why it wouldn’t be?
My opinion is the same as Anavex's legal council, so need for me to opine further.
It's always amusing to see someone declare war on a fact.
If something is up private equity financing wise, we'll know by end of Q4.
As a market aside, I know for a fact private equity has a war chest of money the needs to be invested and where better than in $AVXL to deploy it upon an EMA filing especially now that investor2014 is onboard with the +83% approval rate. LOL
There is some evidence: at the ASM he admitted the juvenile Rett study was too small and was poorly designed and outlined a new trial with 2.5X as many patients and a larger % placebo. And Dr. Jin was hired to ensure they don't fail statistically in the future. We haven't see the PD trial design or the other new pivotal trial designs yet, but there is reason to hope.
I have a fair amount of experience in the field of U.S. Securities Class Action law and systems to support the associated workflows.
I’m not in the business of advising lawyers though or investors, but have read and analysed more cases than I ever imagined I would to design systems and with input from several of the law firms in that field.
You must have as well given your solid opinion on this case in opposition to my own?
Class action is heading toward a settlement, and it seems Misleading shenanigans are finally catching up with him. While he personally has nothing to lose, shareholders stand to suffer significantly. The BOD needs to wake up and take action—fire him and claw back all his options and bonuses.
Lately, he’s been talking about health equity and Amazon shipping, which seems absurd. Who ships prescription medicine through Amazon, aside from maybe vitamins? His talks (blabbering) and actions are 180 apart.
I'm wondering if AVXL sponsored this conference too, just seems kind of random for Missling/Nell/Anavex to all be tagged when they seemingly weren't presenting anything - most of the other tags are for analysts, only a couple for those working in other drug development companies.
https://www.linkedin.com/posts/jennifer-k-zimmons-phd-mba_healthcare-banking-research-activity-7242941803866247169-SWXH?utm_source=share&utm_medium=member_desktop
So now you have dreams of being the lawyer against Anavex... LOL?!? You're taking your team FUD role too seriously.
If only the Blum plaintiff lawyer was being advised by Investor2014.
If I was the Blum plaintiff lawyer my next step would be to ask for discovery.
Since AVATAR had no U.S. trial sites or an IND filed with FDA, I would want to see evidence from Anavex that a regulatory authority eg. HMRA in U.K. recommended and/or accepted the use RSBQ evaluated as AUC rather than Baseline to EOT. That is key to the case and if Anavex can’t produce that evidence it’s very likely they will need to settle.
There’s no evidence whatsoever that Missling has ever learned from his mistakes or that he ever will.
So I got that going for me...which is nice... any Caddyshack fans out there?!?
The chances of further endpoint creativity has dropped with the legal complaint, the pending FDA guidance, and the hiring of Jin. Missling very likely learns from mistakes.
It's interesting that the Avatar SPA has not come up in the complaints or MTDs. Was discovery served yet?
Wrong on both counts, but I’ve come to expect that.
In case you're missing my point, neither case is of merit and both will be dismissed on similar grounds as are most class action lawsuits against biotechs.
So to be clear by saying "digital profit" you're just a pretend long on a paper trade. That makes sense given the continued FUD'ish comments.
Actually I’m in digital profit on my latest $AVXL by a smidgen.
Anyway keep an eye on the Blum case and forget about Huey.
Execution on any of their near term goals are needed in Q4 is a topic of which I have no argument.
And if those T/A folk are to blame for you being long, I see the MACD and as you once mentioned the CMF have both improved. But, on the negative side the broader indexes hitting multiple top resistance levels and not breaking on volume is concerning for equity as an asset class and that's a whole different issue, as the fish do move with the tides. That said, a good T/A break out of the broader markets with confirming volumes will no doubt bring $AVXL higher. The wild card remains stock specific to $AVXL and execution otherwise IMO the stock will continue to move in sympathy with the broader indexes.
I guess you are uniquely qualified to parse all the complexities and come to the right proper and definitive conclusion. Only the elite insiders are privileged to have such insight. Rubbish.
I’m long and hopeful that Missling and his backland isn’t completely insane knowing that not filing the MAA this year is very unwise - it needs to happen!
But I might be wrong 😑
Now, now, .... no reflexive negativity and lashing out. LOL! Aren't you a long now? Did those T/A folk trick you into buying a support level? or is there a sense of neutrality in your overall opinion?
Missling’s suit fits better this time. It looks like he has been enjoying some meals lately—probably why he needed a new suit. Still could use a haircut—his disheveled look is getting a bit stale.
I'm commenting on the papers listed the link.
Research costs money, and we all know $AVXL has an untapped S-3 on file.
I would not be surprised in the least to see a financing event upon a price increase. I think it's Cantor's turn to help fill the coffers.
You and Hosai are looking at the separate and ill stated Huey complaint.
The Blum case and their response to the motion dismiss is the one to focus on.
Exactly and after reading the Anavex reply, you can see why so many cases are dismissed due to the plaintiff's failure to meet the required elements to move forward. Also, both sides have lists of case law to back up their stances but this is not a "trial on the papers", this is about meeting thresholds. My guess is for full dismissal.
There is a reason why no new trial has been started, company preserving capital for eventual settlement of class action. Hope BOD makes wise decision and get rid of blabbering buffoon, otherwise this company had no future.
Misleading attending but not presenting? Which is good, otherwise stock would have tanked. Guy never misses any dog and pony show.
So far taking long for release of trial outcomes has meant a need for creativity results presentation, sometimes of the kind that can end in class action complaints.
Joe Rogan (and most others) understand it well...
We're being lied to on a daily basis.
“What the hell did Dr. missing do to piss off the wrong entity?”
He’s an incompetent boob who has enriched himself at shareholders’ expense, that’s what the hell he did.
When do we get the OLE top line data? Has been 3 months since it ended...should come out soon, right?
There was one person looking to put limits on executive compensation - in the event of a buyout, I think. The person that put it forward was passionate but not rude, I think. Their proposal was voted down by a large margin but it was a mechanical not emotional outcome (or that is the way I read it.)
There were people who wanted the stock price to be higher (who doesn't?) There was a physician at the table offering his opinions. There were questions about what happens next with Rett. There were questions about the 3-71 trial, There were questions about the pipeline.
No one, that I recall, was aggressive or directly critical of Christopher Missling. Did someone here report differently?
So far the motion to dismiss has not been granted. Also note there are now two separate cases and imo the Bloom case and that response to the motion to dismiss is the one we now wait to see the outcome of. Forget the Huey case.
There is no doubt, as I have pointed out way before this case, that AUC was a nonsense attempt to rescue the outcome of the AVATAR trial, which to date Missling has refused to reveal the Baseline to EOT RSBQ result with CGI-I anchored or not. From the data we have seen it is clear why Missling is not keen on showing that originally published primary outcome measure.
Any near term valuable future for $AVXL rest on the AD MAA being filed and approved. Without that plus a potential class action settlement is a disaster at least for current investors. Good to know that we have an 83% chance approval, right!
With the Bloom case the 40/60 chance of settlement vs. dismissal is at least as valid as your claimed 83% chance of EMA approval for AD.
We have no choice but to wait for the outcome of both and I hope Bloom lands in the 60% bucket and MAA approval in the 83% bucket.
No, I suspect this complaint won't survive.
Followers
|
1085
|
Posters
|
|
Posts (Today)
|
59
|
Posts (Total)
|
469959
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |